ANZCTR search results

This double-blind randomised controlled trial, will assess the relative effectiveness of two different oxytocin regimens for the prevention/treatment of haemorrhage after a caesarean section

The study is being conducted to determine the effect of a novel treatment for sleep apnoea, using a nasal airflow cannula to raise phayngeal pressure. The outcomes assessed will be objective measures of sleep quality, as well as patient assessment of sleep quality. The treatment will be compared to CPAP, which is the current standard treatment for sleep apnoea.

Overall there were two aims of the current study. First, to assess the efficacy of a self-help workbook journal compared with treatment as usual, in attempting to improve coping, quality of life and psychological distress for breast cancer survivors. Second, to qualitatively examine how well the workbook was received. This was the first time a self-management intervention of this type was implemented in an Australian context.

Chronic graft-versus-host disease (cGVHD) is a significant complication for many patients who survive an allogeneic bone marrow transplantation for haematological maligancy. A number of patients with extensive cGVHD have suboptimal control despite adequate steroid-based therapy with other immunosuppression such as cyclosporin. There is no standard salvage treatment to effectively control the disease and avoid long-term toxicity of steroids. This is the first prospective pilot study to explore the use of a single-dose of rituximab plus Low-dose total nodal irradiation (TNI) in the treatment of cGVHD involving the skin and other organ(s). There are a growing body of retrospective data regarding the effectiveness of rituximab and TNI respectively for the treatment of cGVHD. The hypothesis in this pilot study is that the combined treatment approach is safe and effective in treating extensive cGVHD.

Deoxycholate acid, or deoxycholate, is a naturally occuring bile acid produced by the liver as one of several end products of sterol metabolism. In the human body, deoxycholate serves to solubilise dietry fats and facilitate their absorption. ATX-101 (sodium deoxycholate) is being developed by Kythera Biopharmaceuticals as a promising nonsurgical treatment modality for several conditions characterized by unwanted or excessive fat deposition including, but not limited to, lipomas, lipodystrophy in patients with HIV infection, submental and buccal fat deposits, infraorbital fat pockets, and other settings in which liposuction or surgery is the current approach. These surgeries are associated with the known risks of anaesthesia, infection, bleeding, bruising and scarring; the possibility of poor outcomes, adn the expected discomfort and 'down-time' for the patient. Given the risks, which are well-established and documented, the growing populatiry of these procedures is testament to the psychological importance of self-image and to the benefir realised by subjects who seek them. The need for an improved, legitimate and minimally invasive product for reduction of localised fat deposits is substantiated by th esignificant and growing popularity of Lipostabil@ and other unapporved extemporaneous mixtures of phosphatidylcholine/deoxycholate (PC/DC). The objectives of this study are to 1. to determine the safety and tolerability of ATX-101 injections at one concentration and three dosing paradigms, relative to placebo, and 2. to evaluate the potential efficacy of ATX-101, relative to placebo, in reducing SMF, and thereby achieve improvement as judged by the Investigator and participant.

This study will determine whether a specific balance strategy training program is an effective form of exercise for healthy, but less active women aged between 40 to 60 years that can control the rate of decline in balance and sensori-motor function across the menopause transition. Whether participation leads to adoption of more active lifestyle will also be observed. A similar though not quite as challenging evidence based program that targeted the multiple elements of balance has been shown to be effective in older adults. This study will determine if undertaken during the pre-clinical period of balance decline it helps to prevent/reverse the detrimental balance decline that occurs in women during the menopause transition. Should the participants sustain the level of activity post- intervention a safer, healthier lifestyle is likely to ensue evidenced by enhanced self-perceived health status, reduction in fall rate and increased cardiovascular fitness. The study will also look at factors associated with compliance and motivation with uptake of exercise to develop more effective strategies for implementation of programs that are attractive and beneficial for this age group.

The purpose of this study is to evaluate the clinical usefulness of a new diagnostic laser that has been developed at the University of Western Australia. The device is an imaging tool that can make various measurements of the inside of the lungs to help improve our understanding of the lungs in health and disease. Current lung function tests give us information about the lungs as a whole but do not tell us about specific regions within the lungs. Most lung disorders affect different parts of the lungs and to different degrees. Many of these changes are related to the varying degrees of “stiffness” within the air tubes, but at present doctors don’t have adequate tools to measure this airway property. We have developed an optical imaging technique that we think may provide a way to measure these properties. The system has been developed by two research groups, the West Australian Sleep Disorders Research Institute at Sir Charles Gairdner Hospital and the Optical and Biomedical Engineering Laboratory at the University of Western Australia. We have had encouraging results using this device in the upper airway (throat) of awake, sleeping and anaesthetised volunteers and have started using it in patients with windpipe cancers to improve their care. We would now like to use the system to make measurements of airway “stiffness” which we think will help understand lung diseases such as asthma, chronic obstructive pulmonary disease and bronchiectasis.

A randomized, open-label, 4 week trial. Twenty (22) eligible participants will be randomly assigned to receive 1:1 to raltegravir 400mg bid or ritonavir 100mg mane with food. Planned sample size: Twenty two (22) eligible participants.

The study aims to determine if the early administration of clotting factors (ie. FFP) to patients with a procoagulant coagulopathy following snake envenoing will speed the patient recovery of clotting function. A secondary aim to confirm that smaller doses of antivenom are sufficient for the treatment of coagulopathy.

The aim of the study is to prospectively measure the morbidity in children under 5 years of age hospitalised with influenza as well as the indirect burden on their families during one influenza season. This enhanced surveillance data will serve to accurately assess the cost effectiveness of influenza vaccination in young children.